XLO Xilio Therapeutics, Inc.
Listings ·
Xilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.
Nasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.
Nasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.
Leerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $43.8 million | $6.3 million |
| Research and development | $56.0 million | $41.2 million |
| Net income (loss) | -$35.0 million | -$58.2 million |
| Cash from operations | -$5.0 million | -$18.4 million |
| Cash and equivalents | $137.5 million | $55.3 million |
Our latest story on this, dated Oct 3, 2025: "Xilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 11, 2025: "Xilio Therapeutics sets up $50,000,000 at-the-market stock program with Leerink". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 28, 2025: "Xilio Therapeutics gets Nasdaq notice over stockholders' equity below $10.0 million". The story links the filing or release it is based on. Read the story.
Xilio Therapeutics, Inc. trades under the ticker XLO on NASDAQ.
Xilio Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Xilio Therapeutics, Inc. is 1840233. Its filings are on SEC EDGAR.
5,782,511 shares as of 2026-03-18, per the cover page of its 10-K filed 2026-03-23.
Our directory records Xilio Therapeutics, Inc. under United States.
Our directory classifies Xilio Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Xilio Therapeutics, Inc. is US98422T2096.
aibio.space lists Xilio Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$43.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Xilio Therapeutics, Inc. reported a net loss of $35.0 million for the fiscal year ended Dec 31, 2025, and used $5.0 million of cash in operations, per its annual report to the SEC.
$56.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 424B5. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio